Company Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Market Closed - London S.E. 11:35:21 2024-05-21 am EDT 5-day change 1st Jan Change
331.5 GBX -0.15% Intraday chart for Haleon plc +0.79% +3.06%

Business Summary

Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows:

- oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.;

- Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.;

- medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.;

- respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.;

- vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.

Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).

Number of employees: 25,408

Sales per Business

GBP in Million2022Weight2023Weight Delta
Oral Health
27.7 %
2,957 27.2 % 3,136 27.7 % +6.05%
Pain Relief
23.5 %
2,551 23.5 % 2,652 23.5 % +3.96%
Digestive Health and Other
18.9 %
2,096 19.3 % 2,138 18.9 % +2.00%
Respiratory Health
15.4 %
1,579 14.5 % 1,736 15.4 % +9.94%
Vitamins, Minerals and Supplements
14.5 %
1,675 15.4 % 1,640 14.5 % -2.09%

Sales per region

GBP in Million2022Weight2023Weight Delta
EMEA and Latin America
40.2 %
4,270 39.3 % 4,545 40.2 % +6.44%
North America
37.1 %
4,116 37.9 % 4,195 37.1 % +1.92%
APAC
22.7 %
2,472 22.8 % 2,562 22.7 % +3.64%

Managers

Managers TitleAgeSince
Chief Executive Officer 57 21-07-21
Director of Finance/CFO 52 21-11-30
Chief Tech/Sci/R&D Officer - 21-12-15
Investor Relations Contact - -
Sales & Marketing - 21-12-15
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Human Resources Officer - 22-02-28
General Counsel 57 21-12-15

Members of the board

Members of the board TitleAgeSince
Director/Board Member - 22-07-17
Director/Board Member 64 22-07-17
Director/Board Member 57 22-07-17
Director/Board Member 69 22-07-17
Director/Board Member 61 22-07-17
Chairman 59 22-05-22
Director/Board Member 59 23-02-28
Director of Finance/CFO 52 21-11-30
Chief Executive Officer 57 21-07-21
Director/Board Member - 22-07-17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 9,132,301,104 7,461,226,936 ( 81.70 %) 0 81.70 %

Shareholders

NameEquities%Valuation
2,955,063,626 32.36 % 12 562 M p
GSK PLC
4.219 %
385,320,110 4.219 % 1 638 M p
Dodge & Cox
2.532 %
231,253,000 2.532 % 983 M p
The Vanguard Group, Inc.
2.405 %
219,663,000 2.405 % 934 M p
Norges Bank Investment Management
1.621 %
148,004,000 1.621 % 629 M p
MFS International (UK) Ltd.
1.379 %
125,915,466 1.379 % 535 M p
GIC Pte Ltd. (Investment Management)
1.045 %
95,442,000 1.045 % 406 M p
BlackRock Fund Advisors
1.009 %
92,189,000 1.009 % 392 M p
BlackRock Advisors (UK) Ltd.
0.9963 %
90,981,000 0.9963 % 387 M p
BlackRock Investment Management (UK) Ltd.
0.9364 %
85,518,000 0.9364 % 364 M p
NameEquities%Valuation
Dodge & Cox
3.875 %
176,953,251 3.875 % 1 486 M p
Fidelity Management & Research Co. LLC
1.835 %
83,806,041 1.835 % 704 M p
ClearBridge Investments LLC
0.8420 %
38,446,978 0.8420 % 323 M p
Fisher Asset Management LLC
0.3148 %
14,376,303 0.3148 % 121 M p
Wellington Management Co. LLP
0.2933 %
13,392,179 0.2933 % 112 M p
Citadel Securities GP LLC
0.2881 %
13,156,009 0.2881 % 111 M p
AllianceBernstein LP
0.2360 %
10,774,072 0.2360 % 91 M p
Merrill Lynch International
0.2319 %
10,590,597 0.2319 % 89 M p
RBC Private Counsel (USA), Inc.
0.1963 %
8,961,261 0.1963 % 75 M p
Aristotle Capital Management LLC
0.1946 %
8,887,558 0.1946 % 75 M p

Company contact information

Haleon Plc

The Heights Building 5, 1st Floor

KT13 0NY, Weybridge

+44 1932 822000

http://www.haleon.com
address Haleon plc(HLN)

Group companies

NameCategory and Sector
Pharmaceuticals: Major
Drugstore Chains
Regional Banks
Financial Conglomerates
Medical/Nursing Services
Financial Conglomerates
Pharmaceuticals: Other
Financial Conglomerates

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.315 GBP
Average target price
3.62 GBP
Spread / Average Target
+9.20%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW